2026 Q2 - tulosraportti
63 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 9 | - | - | ||
| 155 | - | - | ||
| 100 | - | - | ||
| 288 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·15 t sittenWell.... then I guess we have the answer as to why the stock dropped so sharply.... damn how they vote through incentive programs and other compensations in so many companies nowadays. There's no money left for us other shareholders, as well as product development and marketing. I'm so tired..... 🧐I have not written anything about the fees standing out, but rather that I do not look kindly upon companies with large fees essentially deciding for themselves what their fees should be. This applies regardless of whether they are large or small companies. I myself have represented very large holdings of large companies in listed companies and seen how general meetings are pushed through without regard for shareholders. Hence my view on this. Your comment about experienced and competent board members, I cannot personally assess how much business they will generate. Here, I would like to see a more detailed governance of fees and options linked to performance improvement per person in some way, or in any case, entirely linked to the net result per year, balanced over 3 years or 5 years. Because, of course, it takes time to build a business, and of course, one brings in respective individuals with the assumption that they will take on their assignment for a number of years.
·1 päivä sittenThose of us who are long-term investors stick to the facts and await the decision in December. If one wants to top up, it is appropriate to do so now. It can of course continue to go down a bit more, but on Wednesday we face a further step in the process. https://swedenbio.se/kalendarium/lsx-congress-usa/ LSX in Boston, Hansa Biopharma participates on Wednesday in LSX Congress USA. It is one of the most significant international congresses for business development, investments, and strategic partnerships within the life science sector. The main purpose of LSX is to arrange exclusive one-on-one meetings between the management of biotech companies and American institutional investors as well as potential pharmaceutical partners Platform for new gene therapy agreements: Since LSX USA gathers global executives in business development (Business Development), it is precisely here that Hansa will pitch imlifidase to new gene therapy companies – in line with the goal of finding more collaborations beyond Sarepta, Genethon, and AskBio My conclusion is that a short-term decline does not mean that the share price during one week in September dictates the share price in December. Another conclusion is that someone who sits and draws lines on their computer can continue to dream that it is their lines and not the market that controls the price… Now I will not spend more time on negative individuals, we look forward to the journey towards December and future collaborations in gene therapy. I https://news.cision.com/se/hansa-biopharma-ab/r/hansa-biopharma-deltar-i-lsx-congress-usa-i-boston,c4398924
1 päivä sittenWith 22 procent in Hansa, one might think you were a little bias ;) Good luck
·18.9. · MuokattuIt's just unbelievable how it just keeps falling and falling price 48 early September and now 36 = 25% down
·16.9.Dilution ? A potential private placement in connection with a listing in the USA could lead to a dilution of 20%, I have compared with Calliditas IPO in the USA. Market conditions are likely to affect a potential discount. I estimate that they might make a decision on the listing some month after the extraordinary general meeting. My opinion and not advice.Good that you now bring up Calliditas as an example, You omit important facts. Perhaps you should write a bit about what happened to Calliditas afterwards. Since you omit this, I will add it. . Calliditas' management is now in Hansas' management. The history - I was myself part of the journey with an initial average cost of 57. Calliditas was then sold. Bid price: 208 kronor cash per share (as well as 416 kronor per American Depositary Share, ADS).Bid premium: The price implied a very high bid premium of 83 percent compared to the closing price the day before the bid was made. Facts and not advice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 80 230 | 80 230 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 80 230 | 80 230 | 0 | 0 |
2026 Q2 - tulosraportti
63 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sittenWell.... then I guess we have the answer as to why the stock dropped so sharply.... damn how they vote through incentive programs and other compensations in so many companies nowadays. There's no money left for us other shareholders, as well as product development and marketing. I'm so tired..... 🧐I have not written anything about the fees standing out, but rather that I do not look kindly upon companies with large fees essentially deciding for themselves what their fees should be. This applies regardless of whether they are large or small companies. I myself have represented very large holdings of large companies in listed companies and seen how general meetings are pushed through without regard for shareholders. Hence my view on this. Your comment about experienced and competent board members, I cannot personally assess how much business they will generate. Here, I would like to see a more detailed governance of fees and options linked to performance improvement per person in some way, or in any case, entirely linked to the net result per year, balanced over 3 years or 5 years. Because, of course, it takes time to build a business, and of course, one brings in respective individuals with the assumption that they will take on their assignment for a number of years.
- ·1 päivä sittenThose of us who are long-term investors stick to the facts and await the decision in December. If one wants to top up, it is appropriate to do so now. It can of course continue to go down a bit more, but on Wednesday we face a further step in the process. https://swedenbio.se/kalendarium/lsx-congress-usa/ LSX in Boston, Hansa Biopharma participates on Wednesday in LSX Congress USA. It is one of the most significant international congresses for business development, investments, and strategic partnerships within the life science sector. The main purpose of LSX is to arrange exclusive one-on-one meetings between the management of biotech companies and American institutional investors as well as potential pharmaceutical partners Platform for new gene therapy agreements: Since LSX USA gathers global executives in business development (Business Development), it is precisely here that Hansa will pitch imlifidase to new gene therapy companies – in line with the goal of finding more collaborations beyond Sarepta, Genethon, and AskBio My conclusion is that a short-term decline does not mean that the share price during one week in September dictates the share price in December. Another conclusion is that someone who sits and draws lines on their computer can continue to dream that it is their lines and not the market that controls the price… Now I will not spend more time on negative individuals, we look forward to the journey towards December and future collaborations in gene therapy. I https://news.cision.com/se/hansa-biopharma-ab/r/hansa-biopharma-deltar-i-lsx-congress-usa-i-boston,c43989241 päivä sittenWith 22 procent in Hansa, one might think you were a little bias ;) Good luck
- ·18.9. · MuokattuIt's just unbelievable how it just keeps falling and falling price 48 early September and now 36 = 25% down
- ·16.9.Dilution ? A potential private placement in connection with a listing in the USA could lead to a dilution of 20%, I have compared with Calliditas IPO in the USA. Market conditions are likely to affect a potential discount. I estimate that they might make a decision on the listing some month after the extraordinary general meeting. My opinion and not advice.Good that you now bring up Calliditas as an example, You omit important facts. Perhaps you should write a bit about what happened to Calliditas afterwards. Since you omit this, I will add it. . Calliditas' management is now in Hansas' management. The history - I was myself part of the journey with an initial average cost of 57. Calliditas was then sold. Bid price: 208 kronor cash per share (as well as 416 kronor per American Depositary Share, ADS).Bid premium: The price implied a very high bid premium of 83 percent compared to the closing price the day before the bid was made. Facts and not advice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 9 | - | - | ||
| 155 | - | - | ||
| 100 | - | - | ||
| 288 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 80 230 | 80 230 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 80 230 | 80 230 | 0 | 0 |
2026 Q2 - tulosraportti
63 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 22.7. | ||
2026 Q1 - tulosraportti 23.4. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 30.10.2025 | ||
2025 Q2 - tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·15 t sittenWell.... then I guess we have the answer as to why the stock dropped so sharply.... damn how they vote through incentive programs and other compensations in so many companies nowadays. There's no money left for us other shareholders, as well as product development and marketing. I'm so tired..... 🧐I have not written anything about the fees standing out, but rather that I do not look kindly upon companies with large fees essentially deciding for themselves what their fees should be. This applies regardless of whether they are large or small companies. I myself have represented very large holdings of large companies in listed companies and seen how general meetings are pushed through without regard for shareholders. Hence my view on this. Your comment about experienced and competent board members, I cannot personally assess how much business they will generate. Here, I would like to see a more detailed governance of fees and options linked to performance improvement per person in some way, or in any case, entirely linked to the net result per year, balanced over 3 years or 5 years. Because, of course, it takes time to build a business, and of course, one brings in respective individuals with the assumption that they will take on their assignment for a number of years.
- ·1 päivä sittenThose of us who are long-term investors stick to the facts and await the decision in December. If one wants to top up, it is appropriate to do so now. It can of course continue to go down a bit more, but on Wednesday we face a further step in the process. https://swedenbio.se/kalendarium/lsx-congress-usa/ LSX in Boston, Hansa Biopharma participates on Wednesday in LSX Congress USA. It is one of the most significant international congresses for business development, investments, and strategic partnerships within the life science sector. The main purpose of LSX is to arrange exclusive one-on-one meetings between the management of biotech companies and American institutional investors as well as potential pharmaceutical partners Platform for new gene therapy agreements: Since LSX USA gathers global executives in business development (Business Development), it is precisely here that Hansa will pitch imlifidase to new gene therapy companies – in line with the goal of finding more collaborations beyond Sarepta, Genethon, and AskBio My conclusion is that a short-term decline does not mean that the share price during one week in September dictates the share price in December. Another conclusion is that someone who sits and draws lines on their computer can continue to dream that it is their lines and not the market that controls the price… Now I will not spend more time on negative individuals, we look forward to the journey towards December and future collaborations in gene therapy. I https://news.cision.com/se/hansa-biopharma-ab/r/hansa-biopharma-deltar-i-lsx-congress-usa-i-boston,c43989241 päivä sittenWith 22 procent in Hansa, one might think you were a little bias ;) Good luck
- ·18.9. · MuokattuIt's just unbelievable how it just keeps falling and falling price 48 early September and now 36 = 25% down
- ·16.9.Dilution ? A potential private placement in connection with a listing in the USA could lead to a dilution of 20%, I have compared with Calliditas IPO in the USA. Market conditions are likely to affect a potential discount. I estimate that they might make a decision on the listing some month after the extraordinary general meeting. My opinion and not advice.Good that you now bring up Calliditas as an example, You omit important facts. Perhaps you should write a bit about what happened to Calliditas afterwards. Since you omit this, I will add it. . Calliditas' management is now in Hansas' management. The history - I was myself part of the journey with an initial average cost of 57. Calliditas was then sold. Bid price: 208 kronor cash per share (as well as 416 kronor per American Depositary Share, ADS).Bid premium: The price implied a very high bid premium of 83 percent compared to the closing price the day before the bid was made. Facts and not advice.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 | - | - | ||
| 9 | - | - | ||
| 155 | - | - | ||
| 100 | - | - | ||
| 288 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 80 230 | 80 230 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 80 230 | 80 230 | 0 | 0 |